Nuveen Asset Management LLC Purchases 353,070 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Nuveen Asset Management LLC lifted its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 37.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,296,366 shares of the medical instruments supplier's stock after purchasing an additional 353,070 shares during the period. Nuveen Asset Management LLC owned 3.20% of AngioDynamics worth $11,875,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in ANGO. SBI Securities Co. Ltd. bought a new stake in shares of AngioDynamics during the fourth quarter worth $28,000. R Squared Ltd bought a new stake in shares of AngioDynamics during the fourth quarter worth $49,000. US Bancorp DE grew its holdings in shares of AngioDynamics by 1,938.0% during the fourth quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock worth $61,000 after purchasing an additional 6,376 shares during the last quarter. Quinn Opportunity Partners LLC acquired a new position in AngioDynamics during the 4th quarter valued at about $92,000. Finally, Graham Capital Management L.P. acquired a new position in AngioDynamics during the 4th quarter valued at about $106,000. Institutional investors own 89.43% of the company's stock.

AngioDynamics Stock Performance

AngioDynamics stock traded up $0.16 during trading hours on Friday, reaching $10.16. 911,545 shares of the company's stock traded hands, compared to its average volume of 561,312. AngioDynamics, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $13.50. The firm's 50 day moving average is $9.47 and its 200-day moving average is $9.59. The firm has a market capitalization of $412.57 million, a price-to-earnings ratio of -1.80 and a beta of 0.58.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.16. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm had revenue of $72.00 million for the quarter, compared to analyst estimates of $70.30 million. The company's revenue was down 4.3% compared to the same quarter last year. Analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $16.00 target price (up from $15.00) on shares of AngioDynamics in a research report on Monday, April 7th.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.